Geron

GERN

Market cap $791M

Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations

How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales ramp potential.

FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 shares of its common stock, consisting of stock options to purchase an aggregate of 644,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 322,000 shares of common stock, to sixteen newly hired employees as an inducement material to their acceptance of employment with Geron.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on September 4, 2025 at the 2025 Wells Fargo Healthcare Conference in Boston, MA. A live webcast of the presentation will be available at ir.geron.com and will be posted on the Investors and Media section of Geron's website. The webcast will be archived and available for replay for 30 days following t.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 shares of its common stock, consisting of stock options to purchase an aggregate of 348,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 174,000 shares of common stock, to eleven newly hired employees as an inducement material to their acceptance of emplo.

Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock options were granted on August 7, 2025. The stock options have an exercise price of $1.30 per share, wh.

Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has already peaked, echoing past misjudgments seen with AUPH. A run-up into an interim readout from IMpactMF, GERN's trial of imetelstat in myelofibrosis, could begin in H1'26, since results are expected in H2'26.

Geron Corporation (NASDAQ:GERN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim President & Chief Executive Officer and Director Harout Semerjian - Corporate Participant James Ziegler - Executive VP & Chief Commercial Officer Joseph Emile Eid - Executive Vice President of Research Development Michelle J. Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Conference Call Participants Corinne Johnson - Goldman Sachs Group, Inc., Research Division Emily Claudia Bodnar - H.C.